Circulating Tumor Cell Detection in Lung Cancer: But to What End?
AbstractThe understanding of the natural history and biology of lung cancer has been enhanced by studies into circulating tumor cells (CTCs). Fundamental and translational research, as well as clinical trials in the characterization and behavior of these cells, have constantly contributed to improving understanding within the domain of thoracic oncology. However, the use of these CTCs as prognostic and predictive biomarkers has not been adopted to the same extent as circulating free DNA (cf-DNA) in plasma, in the daily practice of thoracic oncologists. However, recent technological advances have firmly put the detection and characterization of CTCs in thoracic oncology back on the agenda, and have opened up perspectives for their routine clinical use. This review discusses the major advances of using CTCs in the domain of thoracic oncology, as well as the envisaged short- and long-term prospects. View Full-Text
Share & Cite This Article
Hofman, V.; Heeke, S.; Marquette, C.-H.; Ilié, M.; Hofman, P. Circulating Tumor Cell Detection in Lung Cancer: But to What End? Cancers 2019, 11, 262.
Hofman V, Heeke S, Marquette C-H, Ilié M, Hofman P. Circulating Tumor Cell Detection in Lung Cancer: But to What End? Cancers. 2019; 11(2):262.Chicago/Turabian Style
Hofman, Véronique; Heeke, Simon; Marquette, Charles-Hugo; Ilié, Marius; Hofman, Paul. 2019. "Circulating Tumor Cell Detection in Lung Cancer: But to What End?" Cancers 11, no. 2: 262.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.